| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2025 |
| Sales | 3,510 | 3,710 | 2,330 | 0 | 0 |
| Sales Growth | -5.39% | +59.23% | unch | unch | unch |
| Net Income | -40,250 | -30,150 | -17,790 | -8,870 | 0 |
| Net Income Growth | -33.50% | -69.48% | -100.56% | unch | unch |
Ayala Pharmaceuticals Inc (AYLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala Pharmaceuticals Inc. is based in Rehovot, Israel.
Fiscal Year End Date: 12/31